Catalog No.
Product Name
Application
Product Information
Citations
-
α-Amylase Inhibitor
α-Amylase-IN-1 is a potent α-Amylase inhibitor with an IC50 value of 0.5509 μM, making it an effective tool for research in carbohydrate metabolism. Additionally, it exhibits antioxidant activity, demonstrating an IC50 value of 53.49 μM for scavenging DPPH free radicals. This compound is valuable for studies related to diabetes management and the effects of oxidative stress on cellular health. -
α-Amylase Inhibitor
3,5,6,7,8,4'-Hexamethoxyflavone is an α-Amylase inhibitor, demonstrating 28.3% inhibitory activity at a concentration of 500 μM. This compound is valuable in studying carbohydrate metabolism and has potential applications in diabetes research and obesity management. Its inhibitory properties make it suitable for investigating metabolic pathways and developing therapeutic strategies targeting α-Amylase. -
MAO Inhibitor
MAO-B-IN-46 is a selective inhibitor of human monoamine oxidase B (hMAO-B) with an IC50 of 26.8 nM, exhibiting weak inhibition of hMAO-A (IC50: 7.2054 μM). This compound also functions as an α-amylase inhibitor, presenting an IC50 of 19.46 μM. Its neuroprotective properties demonstrate the potential for investigating neurodegenerative conditions such as Parkinson's disease, while its ability to scavenge DPPH and ABTS free radicals (IC50 values of 17.86 μM and 17.71 μM, respectively) highlights its relevance in research related to oxidative stress and diabetes. MAO-B-IN-46 shows minimal toxicity to human gingival fibroblasts and SH-SY5Y cells. -
α-Amylase Inhibitor
α-Amylase-IN-9 is a potent α-Amylase inhibitor with an IC50 value of 14.64 μM. This compound is specifically designed for use in diabetes research, aiding in the exploration of glucose regulation and carbohydrate metabolism. Its inhibitory activity on α-Amylase makes it a valuable tool for studying potential therapeutic approaches to managing hyperglycemia and related metabolic disorders. -
HPA Inhibitor
HPA-IN-2 is a potent and selective inhibitor of human pancreatic α-amylase (HPA) with an IC50 value of 8.2 μM, demonstrating its efficacy in modulating carbohydrate digestion. In contrast, it shows significantly weaker inhibition of α-glucosidase with an IC50 of 450.7 μM. This compound is utilized in research focused on diabetes and metabolic disorders, particularly in understanding the regulation of carbohydrate metabolism. -
α-glucosidase/α-amylase Inhibitor
Sekikaic acid is a potent inhibitor of α-glucosidase and α-amylase, playing a significant role in the management of carbohydrate metabolism. Its biological activities include hypolipidemic and antioxidant effects, as well as antidiabetic properties, making it a valuable compound for research into metabolic disorders. Sekikaic acid has been shown to significantly reduce LDL cholesterol, total cholesterol, and triglyceride levels, while also promoting the regeneration of pancreatic beta cells. This compound is an essential tool for studies focused on diabetes and lipid metabolism. -
α-amylase Inhibitor
α-Amylase-IN-12 is a selective inhibitor of α-amylase, exhibiting a mixed inhibition mechanism with an IC50 value of 0.15 mM. It also demonstrates an IC50 of 9.40 mM against α-glucosidase. This compound promotes glucose uptake in yeast cells and shows notable antiglycation activity at elevated concentrations. α-Amylase-IN-12 is applicable in diabetes research, providing insights into carbohydrate metabolism and potential therapeutic strategies. -
α-Amylase Inhibitor
Onjisaponin R serves as a specific α-amylase inhibitor, pivotal in regulating carbohydrate metabolism. It demonstrates significant potential in diabetes research by modulating blood glucose levels and enhancing glycemic control. This compound is essential for studies exploring therapeutic strategies for diabetes management and related metabolic disorders. -
α-glucosidase/α-amylase Dual Inhibitor
2,7"-Phloroglucinol-6,6'-bieckol functions as a dual inhibitor of α-glucosidase and α-amylase, exhibiting IC50 values of 6.94 μM and 23.35 μM, respectively. This compound has demonstrated the ability to mitigate postprandial hyperglycemia in diabetic mouse models. 2,7"-Phloroglucinol-6,6'-bieckol is valuable for research focused on diabetes and glucose metabolism. -
α-glucosidase/α-amylase enzyme Dual Inhibitor
α-Amylase/α-Glucosidase-IN-7 is a competitive dual inhibitor targeting α-glucosidase and α-amylase, demonstrating IC50 values of 18.52 µM and 20.25 µM, respectively. Additionally, this compound effectively inhibits acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), with IC50 values of 9.25 µM and 10.06 µM. α-Amylase/α-Glucosidase-IN-7 is valuable for research applications related to diabetes and Alzheimer’s disease. -
α-Amylase Inhibitor
Quercetin 3-(6″-caffeoylsophoroside) is a potent α-amylase inhibitor with an IC50 of 73.66 μg/mL, demonstrating significant potential for antidiabetic applications. Isolated from the hydro-methanolic extract of Cardamine hirsuta Linn., this compound exerts its biological activity by reducing oxidative stress and inhibiting α-amylase. It is a valuable tool for researchers investigating the mechanisms and treatment strategies for diabetes mellitus. -
α-Amylase/α-Glucosidase Inhibitor
3,4,6-Tri-O-galloyl-D-glucose is a mixed-type inhibitor of α-amylase and α-glucosidase, with an IC50 of 334.6 μM against porcine α-amylase and 46.5 μM against yeast α-glucosidase. This compound demonstrates free radical scavenging capabilities, ferric-reducing power, and significant antioxidant activity. Its properties make it a valuable tool for research focused on diabetes and related metabolic disorders. -
Antidiabetic Agent
Antidiabetic Agent 5 is an inhibitor of α-glucosidase and α-amylase, demonstrating IC50 values of 3.91 μM and 8.89 μM, respectively. This compound effectively reduces sugar levels in biological systems, making it a valuable tool for the study of type II diabetes. Antidiabetic Agent 5 offers potential insights into therapeutic strategies for managing glycemic control and advancing diabetes research. -
Sesquiterpene Gglycoside
Dendromoniliside D is a sesquiterpene glycoside that functions as an α-amylase inhibitor. Isolated from Dendrobium nobile, it exhibits significant potential in cancer research, particularly concerning liver, lung, and breast cancers. Its biological activity makes it a valuable compound for studies focused on metabolic regulation and cancer therapeutics. -
α-Amylase Inhibitor
α-Amylase-IN-13 is a selective inhibitor of α-amylase that operates via a mixed inhibition mechanism (IC50 = 0.71 μM). This brain-penetrant compound has demonstrated the ability to significantly lower blood glucose levels in diabetic rat models and promotes notable histopathological improvements in the kidney, liver, and pancreas. α-Amylase-IN-13 is a valuable tool for investigating diabetic complications and evaluating therapeutic strategies for diabetes management. -
Triterpenoid Saponin
Ladyginoside A is a triterpenoid saponin derived from the leaves of Polyscias fruticosa. It exhibits inhibitory activity against α-amylase and α-glucosidase, making it relevant for the regulation of carbohydrate metabolism. Additionally, Ladyginoside A shows potential anti-inflammatory properties and may stabilize mast cells. This compound is suitable for investigations into inflammation and metabolic disorders, including diabetes. -
α-Amylase Inhibitor
Gibbestatin B is an α-amylase inhibitor that targets the expression of α-amylase induced by gibberellin in de-embryonated rice and barley, with an IC50 ranging from 25 to 50 ppm. Its specific action on α-amylase makes it a valuable tool in studying carbohydrate metabolism and plant physiological responses to gibberellin. Notably, Gibbestatin B exhibits no antibacterial, anti-yeast, or antifungal activity at concentrations of 100 ppm, allowing for focused research on its enzymatic inhibition. -
Component Of Phospholipids
Docosapentaenoic acid (22n-3) sodium is a key component of phospholipids, influencing cell membrane integrity and function. It exhibits inhibitory activity against α-amylase and α-glucosidase with IC50 values of 17 μg/mL and 22 μg/mL, respectively, contributing to its potential applications in metabolic research. Additionally, Docosapentaenoic acid (22n-3) sodium has been shown to enhance cell viability and demonstrates mild anti-inflammatory properties, making it useful for various biological studies. -
α-Amylase Inhibitor
α-Amylase-IN-10 is a potent inhibitor of α-amylase, exhibiting an IC50 value of 5.00 µM. This compound is valuable for research focusing on type 2 diabetes mellitus, providing insights into carbohydrate metabolism and potential therapeutic strategies. Its ability to modulate α-amylase activity makes it a useful tool in studies aimed at understanding metabolic disorders and developing anti-diabetic agents. -
α-Amylase Inhibitor
α-Amylase-IN-7 is a specific inhibitor of α-Amylase, exhibiting an IC50 value of 40 μM. This compound demonstrates potential as an antidiabetic agent by regulating carbohydrate metabolism. Research applications may include the study of glycemic control and the development of therapeutic strategies for diabetes management. -
PCSK9 Inhibitor
DC371739 is a potent PCSK9 inhibitor that exhibits oral bioactivity. It effectively reduces the mRNA expression of both PCSK9 and ANGPTL3, while simultaneously increasing the protein expression of LDLR. This compound holds promise for research applications related to hyperlipidemia and the modulation of lipid metabolism. -
CA/MAO-B Inhibitor
CA/MAO-B-IN-1 is a potent dual inhibitor of human brain carbonic anhydrases (CA) and Monoamine Oxidase-B (MAO-B), exhibiting IC50 values of 8.8 nM and 7.0 nM, respectively. This compound demonstrates significant potential for research applications related to neurological conditions, as it may modulate both enzymatic activity and associated pathways. Additionally, in silico predictions suggest favorable oral absorption of 71.9%, making it a relevant candidate for further pharmacological studies. -
CES Inhibitor
Dibromsalicil is a selective inhibitor of carboxylesterases (CES), exhibiting inhibitory activity with IC50 values of 72.7 nM against human intestinal carboxylesterase (hiCE) and 53.5 nM against rabbit liver carboxylesterase (rCE). This compound demonstrates minimal activity against human liver carboxylesterase (hCE1) and cholinesterase, making it a valuable tool for research applications focused on drug metabolism and enzymatic activity modulation. Its specificity for hiCE and rCE positions Dibromsalicil as an important reagent for studying carboxylesterase-related pathways. -
Carrot Carboxylesterase Substrate
Tripropionin, a triglyceride, acts as a substrate for carrot carboxylesterase. It exhibits key biological activity as a hydrolyzable ester, making it suitable for applications in lipid nanoemulsion formulation. This compound can effectively serve as the oil phase for creating high-performance lipid nanoemulsion droplets, facilitating the encapsulation, stable storage, and controlled release of bioactive compounds such as Combretastatin A4. -
hCES2A Inhibitor
Isolicoflavonol is a potent inhibitor of hCES2A (Human carboxylesterase 2), exhibiting reversible and mixed inhibition of fluorescein diacetate hydrolysis. With Ki values below 1.0 μM, it serves as a valuable tool for exploring enzymatic activity and regulation in biochemical research. Its specificity and efficacy make it suitable for investigations into drug metabolism and enzyme kinetics. -
hCES2 Inhibitor
CES2-IN-1 is a reversible and selective inhibitor of human carboxylesterase 2 (hCES2), exhibiting an IC50 value of 6.72 μM. This compound effectively reduces CES2 levels in living cells, making it useful for studies involving drug metabolism. CES2-IN-1 has demonstrated efficacy in preclinical models for conditions such as irinotecan-induced delayed diarrhea and dextran sulfate sodium (DSS)-induced ulcerative colitis, supporting its application in gastrointestinal research. -
Synthetic Reagent
Ethyl phenylglyoxylate, an ethyl ester of phenylglyoxylic acid, serves as a synthetic reagent in chemical research. It is recognized as a potent inhibitor of chicken liver carboxylesterase, despite being a suboptimal substrate. Additionally, Ethyl phenylglyoxylate exhibits photoreactivity, enabling its excited triplet carbonyl to initiate various reactions, including intermolecular hydrogen abstraction, radical coupling, and cross-linking. This compound is valuable for studies involving enzyme inhibition and radical-mediated processes. -
Carboxylesterase Inhibitor
Tanshinone IIA anhydride is a potent irreversible inhibitor of human carboxylesterases, demonstrating Ki values of 1.9 nM for human carboxylesterase 1 and 1.4 nM for human intestinal carboxylesterase. This compound is valuable for studying the regulatory mechanisms of esterases in various biological processes. Its application extends to biochemical studies focused on enzyme inhibition and metabolic pathway analysis. -
CE Inhibitor
1-Methylisatin is a selective carboxylesterase (CE) inhibitor, exhibiting inhibitory constants of 38.2 μM for human isoform CE (hiCE) and 5.38 μM for human carboxylesterase 1 (hCE1). This compound interacts with human adult hemoglobin through hydrophobic binding and electrostatic interactions. 1-Methylisatin serves as a valuable tool for investigating the regulation of drug metabolism and biochemical pathways in vivo. -
PL/hCES1A Inhibitor
Pancreatic lipase/Carboxylesterase 1-IN-1 is a potent inhibitor of pancreatic lipase (PL) and human carboxylesterase 1A (hCES1A), displaying IC50 values of 2.13 µM and 0.055 µM, respectively. This dual inhibition makes it a valuable tool for studying lipid metabolism and the enzymatic pathways related to drug metabolism and detoxification processes. It has potential applications in research focused on obesity, metabolic disorders, and pharmacokinetics. -
hCES2A Inhibitor
Gancaonin I is an isoflavone that serves as a moderate inhibitor of human carboxylesterase 2 (hCES2A) with an IC50 of 1.72 μM. It effectively inhibits the hCES2A-mediated hydrolysis of fluorescein diacetate (FD), making it a valuable tool for research applications involving enzyme regulation and drug metabolism studies. -
Carboxylesterase (CES) Inhibitor
PMPMEase-IN-1 is a selective inhibitor of carboxylesterase (CES) that targets PMPMEase activity, thereby modulating protein methylation processes. This compound demonstrates potential anti-cancer activity by enhancing sensitivity to polyisoprenyl derivatives, with an effective concentration (EC50) observed in inducing degeneration of human neuroblastoma SH-SY5Y cells. By specifically inhibiting PMPMEase, PMPMEase-IN-1 may contribute to the regulation of polyisoprenyl protein metabolism, promoting normal cellular function. Its utility in research could pave the way for therapeutic advancements in treating cancer and degenerative diseases. -
hCES2A Inhibitor
CES2A-IN-3 is a potent inhibitor of human carboxylesterase 2A (hCES2A), acting through a serine-targeting covalent mechanism with an IC50 of 0.12 nM. This compound holds significant promise for research applications related to gastrointestinal disorders, including diarrhea and ulcerative colitis, by modulating enzyme activity linked to these conditions. Its high specificity and efficacy make it an essential tool for exploring hCES2A's role in related biological pathways. -
Flavonoids Compound
Kushenol X is a flavonoid compound derived from the roots of Sophora flavescens, known for its inhibition of β-glucuronidase and human carboxylesterase 2 (hCE2). With IC50 values of 2.07 μM and 3.05 μM respectively, it serves as a valuable tool for studying enzymatic pathways and their roles in pharmacokinetics. This compound is relevant for research in drug metabolism and therapeutic interventions involving glycosylated and esterified compounds. -
Carboxylesterase Inhibitor
Carboxylesterase-IN-4 is a highly potent inhibitor of carboxylesterase, exhibiting an IC50 of 1.58 nM. This compound facilitates research into cholesterolemia by effectively modulating carboxylesterase activity, making it a valuable tool in the study of lipid metabolism and associated disorders. -
Stable Isotope
Ethyl phenylglyoxylate-d5 is a deuterium-labeled derivative of Ethyl phenylglyoxylate, primarily functioning as a stable isotope for chemical research. This compound serves as a synthetic reagent and is recognized as a potent inhibitor of chicken liver carboxylesterase, despite being a poor substrate. Additionally, Ethyl phenylglyoxylate-d5 demonstrates photoreactivity; its excited triplet carbonyl can facilitate intermolecular hydrogen abstraction, radical coupling, and cross-linking reactions, making it valuable in various biochemical studies and synthetic applications. -
Carboxylesterase Inhibitor
Carboxylesterase-IN-5 is an irreversible and competitive inhibitor of carboxylesterase with an IC50 of 21.7 nM for porcine liver carboxylesterase. This reagent is suitable for studies investigating the role of carboxylesterases in metabolic processes and is particularly relevant for research pertaining to hypocholesterolemia. Its specificity and potency make it a valuable tool in biochemical and pharmacological investigations. -
Carboxylesterase Inhibitor
Carboxylesterase-IN-1 is a potent carboxylesterase inhibitor, demonstrating significant inhibitory activity at a concentration of 50 μg/mL. By interfering with carboxylesterase function, it serves as a valuable tool in the study of enzyme regulation and pesticide effects on biological systems. This compound is suitable for research applications focusing on enzyme inhibition and the molecular mechanisms of pesticide action. -
Carboxylesterase (CES) Inhibitor
SQ-24798 is a potent inhibitor of carboxylesterase (CES), specifically designed to bind the zinc ion in the enzyme's active site via its sulfhydryl group, leading to effective enzyme inhibition. This compound exhibits high affinity and specificity, making it a valuable tool in biochemical research focused on understanding CES-related pathways. Its applications include studying drug metabolism and the physiological roles of CES in various biological processes. -
AChE/CES Inhibitor
Heptenophos is a potent inhibitor of acetylcholinesterase (AChE) and plasma carboxylesterase (CES). By obstructing AChE activity, Heptenophos leads to the accumulation of acetylcholine at cholinergic synapses, which can result in symptoms characteristic of organophosphate poisoning. Its rapid toxicity in animal models, such as male albino mice, allows for the investigation of detoxification strategies, particularly in conjunction with agents like obidoxime and Memantine. This compound is widely utilized in research exploring the mechanisms underlying organophosphate effects and potential antidotal treatments. -
Carboxylesterase Substrate
Dibutyl malate serves as a substrate for carboxylesterase, an enzyme critical in the hydrolysis of ester bonds. This compound is particularly useful in biochemical studies investigating enzymatic activity and substrate specificity. It is also applicable in drug metabolism and pharmacokinetic research, aiding in the understanding of ester-containing pharmaceuticals. -
CETP Inhibitor
Obicetrapib potassium is a selective cholesteryl ester transfer protein (CETP) inhibitor that plays a crucial role in regulating lipid metabolism by modulating levels of LDL cholesterol (LDL-C), apolipoprotein B (apoB), and high-density lipoprotein cholesterol (HDL-C). This compound is valuable for research applications focused on dyslipidemia and associated cardiovascular diseases, providing insights into lipid transport mechanisms and potential therapeutic interventions. -
CETP
α-Amylcinnamaldehyde serves as a ligand for the Niemann-Pick type C2 (NPC2) protein, which is crucial for cholesterol transport in various organisms. This compound is significant in the study of moth volatiles and their biological roles, potentially enhancing the understanding of lipid metabolism and transport mechanisms. Its application in research can provide insights into the molecular interactions of NPC2 and the broader implications for lipid-related disorders. -
CETP Inhibitor
CP-532623 is a selective inhibitor of cholesteryl ester transfer protein (CETP), designed to elevate high-density lipoprotein (HDL) cholesterol levels. This compound is a close structural analogue of Torcetrapib and exhibits significant lipophilicity. CP-532623 is utilized in research exploring lipid metabolism, cardiovascular disease, and the modulation of plasma lipoprotein profiles. -
CETP Inhibitor
MK-8262 is a potent inhibitor of cholesteryl ester transfer protein (CETP) with an IC50 of 53 nM and a log D of 5.3, indicating good oral bioavailability. This bistrifluoromethyl analogue is primarily used in research related to coronary heart disease (CHD), specifically studying the dynamics of high-density lipoprotein (HDL) and low-density lipoprotein (LDL). Its inhibition of CETP activity positions it as a valuable tool for investigating lipid metabolism and potential therapeutic approaches for cardiovascular conditions. -
CETP Inhibitor
TAP311 is a selective inhibitor of cholesteryl ester transfer protein (CETP), exhibiting an IC50 of 62 nM. By blocking CETP activity, TAP311 effectively regulates lipid metabolism and enhances high-density lipoprotein (HDL) levels. This compound is valuable for research focused on cardiovascular disease, specifically in studies investigating the role of CETP in lipid regulation and atherosclerosis. -
CETP Inhibitor
BMS-795311 is a potent cholesteryl ester transfer protein (CETP) inhibitor, demonstrating an IC50 of 4 nM in enzyme-based scintillation proximity assays and 0.22 μM in human whole plasma assays. This compound is utilized in research to explore lipid metabolism and its implications in cardiovascular diseases. Its oral bioavailability supports in vivo studies, making it a valuable tool in understanding CETP's role in lipid transport and potential therapeutic strategies for dyslipidemia. -
CETP Inhibitor
CETP-IN-4 is a selective inhibitor of cholesteryl ester transfer protein (CETP), which plays a crucial role in lipid metabolism. By inhibiting CETP activity, this compound has the potential to elevate high-density lipoprotein (HDL) cholesterol levels, thereby influencing cardiovascular health. CETP-IN-4 is suitable for research applications aimed at understanding lipid metabolism disorders and developing therapeutic strategies for cardiovascular diseases. -
CETP Inhibitor
CP-800569 is an orally active inhibitor of cholesteryl ester transfer protein (CETP). This compound has been shown to effectively reduce low-density lipoprotein levels and postprandial triglycerides while increasing high-density lipoprotein levels. CP-800569 is valuable for research focusing on metabolic diseases, providing insights into lipid metabolism and cardiovascular health. -
CETP
BMS-188494 is an inhibitor of cholesteryl ester transfer protein (CETP), which plays a crucial role in lipid metabolism. This compound exhibits significant cholesterol-lowering activity by promoting the degradation of lipoproteins. BMS-188494 is utilized in research to explore its effects on lipid profiles and cardiovascular health, making it valuable for studies focused on atherosclerosis and related metabolic disorders.
